DMAA (Drugs Made In America Acquisition) ROCE %: -0.24% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DMAA Drugs Made In America Acquisition Corp DMAA
14 GF Score
Price $10.70
! 1 Warning Sign
View Full Analysis

What is Drugs Made In America Acquisition ROCE %?

Drugs Made In America Acquisition DMAA +0.09% 14 ROCE % is -0.24% as of Mar. 2026. GuruFocus rates DMAA with a GF Score™ of 14/100. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Drugs Made In America Acquisition's annualized ROCE % for the quarter that ended in Mar. 2026 was -0.24%.

Drugs Made In America Acquisition  (NAS:DMAA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Drugs Made In America Acquisition ROCE % Related Terms

Drugs Made In America Acquisition ROCE % Historical Data

* Premium members only.

The historical data trend for Drugs Made In America Acquisition's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Drugs Made In America Acquisition ROCE % Chart

Drugs Made In America Acquisition Annual Data
Trend Dec24 Dec25
ROCE %
0.00 -2.35

Drugs Made In America Acquisition Quarterly Data
Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial -1.14 -0.23 -0.45 -3.51 -0.24
DMAA
14GF Score
Drugs Made In America Acquisition Corp DMAA
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Drugs Made In America Acquisition ROCE % Calculation

Drugs Made In America Acquisition's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-2.816/( ( (0.551 - 0.796) + (239.919 - 0.376) )/ 2 )
=-2.816/( (-0.245+239.543)/ 2 )
=-2.816/119.649
=-2.35 %

Drugs Made In America Acquisition's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-0.572/( ( (239.919 - 0.376) + (242.035 - 0.492) )/ 2 )
=-0.572/( ( 239.543 + 241.543 )/ 2 )
=-0.572/240.543
=-0.24 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -0.24% mean?
Drugs Made In America Acquisition (DMAA) has a ROCE % of -0.24% as of Mar. 2026.
Is Drugs Made In America Acquisition's ROCE % too high?
Drugs Made In America Acquisition's current ROCE % is -0.24%. Overall, Drugs Made In America Acquisition has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Drugs Made In America Acquisition's ROCE % compare to PLMK and TRGS?
Drugs Made In America Acquisition's ROCE % of -0.24% can be compared against companies in the Diversified Financial Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Diversified Financial Services company?
A good ROCE % depends on the Diversified Financial Services industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Drugs Made In America Acquisition's current ROCE % is -0.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Drugs Made In America Acquisition stock overvalued right now?
Drugs Made In America Acquisition (DMAA) has a current ROCE % of -0.24%. The current ROCE % is -0.24%. Drugs Made In America Acquisition's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Drugs Made In America Acquisition (DMAA), the current ROCE % is -0.24% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Drugs Made In America Acquisition Business Description

Address 420 Lexington Avenue, Suite 1402, New York, NY, USA, 10170
Drugs Made In America Acquisition Corp is a blank check company.
14GF Score

Get the complete analysis for DMAA

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.70
Price